A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

31 March, 2026

TROG Secondary Data Analysis Grant awarded to project to better understand prostate cancer therapy outcomes

LATEST NEWS: 31 March 2026 TROG’s inaugural Secondary Data

26 March, 2026

TROG welcomes new Board members and President-Elect

LATEST NEWS: 26 March 2026 We are delighted to